Telix Pharmaceuticals Ltd: Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
Telix Pharmaceuticals Ltd: CMS proposes payment improvement for radiopharma diagnostics
Telix Pharmaceuticals Ltd: Pending Release of Shares from Voluntary Escrow
Telix Pharmaceuticals Ltd: Appendix 3Y Change in Director Interests - C Behrenbruch
Telix Pharmaceuticals Ltd: Telix Elects to Withdraw from Proposed U.S. Listing
Telix Pharmaceuticals Ltd: Trading Halt
Telix Pharmaceuticals Ltd: Telix Launches Proposed US IPO
Telix Pharmaceuticals Ltd: Telix Completes TLX250-CDx (Zircaix) BLA Submission
Telix Pharmaceuticals Ltd: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
Telix Pharmaceuticals Ltd: Response to ASX Query
Telix Pharmaceuticals Ltd: Telix Submits NDA for New Prostate Cancer Imaging Agent
Telix Pharmaceuticals Ltd: Telix Annual General Meeting - Chairman and CEO Addresses
Telix Pharmaceuticals Ltd: Telix Completes Proof-of-Concept Study for Alpha Therapy
Telix Pharmaceuticals Ltd: Telix has Filed Registration Statement for Proposed US IPO
Telix Pharmaceuticals Ltd: Telix Reports Q1 2024 Financial Performance
Telix Pharmaceuticals Ltd: Telix to File Registration Statement for Proposed US IPO
Telix Pharmaceuticals Ltd: Telix Completes Acquisition of QSAM
Telix Pharmaceuticals Ltd: Pending Release of Shares from Voluntary Escrow
Telix Pharmaceuticals Ltd: Pending Release of Shares from Voluntary Escrow
Telix Pharmaceuticals Ltd: Telix Q1 2024 Revenue and Business Update
No Data